Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773785 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01773785: Clinical Trial Phase 2 study, sponsored by Spectrum Pharmaceuticals.
NCT01773785 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773785, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
Interventions
- DRUG Docetaxel
- DRUG SPI-1620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT01773785 stopped before completion
NCT01773785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01773785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01773785 about?
NCT01773785 is a clinical study titled "Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer". The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
What is the current status of trial NCT01773785?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01773785?
The interventions under investigation include: Docetaxel (DRUG), SPI-1620 (DRUG).
Who is sponsoring clinical trial NCT01773785?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01773785's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia